Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salmeterol dry-powder inhalation - GlaxoSmithKline

Drug Profile

Salmeterol dry-powder inhalation - GlaxoSmithKline

Alternative Names: Salmeterol xinafoate dry-powder inhalation - GlaxoSmithKline; Serevent Accuhaler; Serevent Diskhaler; Serevent Diskus; SN 408 dry-powder inhalation - GlaxoSmithKline

Latest Information Update: 28 Jan 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 04 Mar 2004 Serevent® 50 Diskus® has been approved in Japan for Asthma and Chronic obstructive pulmonary disease
  • 06 May 2003 Launched for Asthma in Australia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top